The effects of coenzyme Q10 supplementation on cardiometabolic markers in overweight type 2 diabetic patients with stable myocardial infarction: A randomized, double-blind, placebo-controlled trial

<p><strong>BACKGROUND</strong>: Limited data are present that have assessed the effects of coenzyme Q10 (CoQ10) intake on cardiometabolic markers in type 2 diabetic patients with coronary heart disease (CHD). This study was done to determine the effects of CoQ10 administration on cardiometabolic markers in overweight diabetic patients with stable myocardial infarction.</p> <p><strong>METHODS: </strong>This randomized double-blind placebo-controlled clinical trial was done among 60 diabetic patients with CHD aged 45-75 years old. Subjects were randomly allocated into two groups to receive either 100 mg/day CoQ10 supplements (n = 30) or placebo (n = 30) for 8 weeks.</p> <p><strong>RESULTS:</strong> Compared with the placebo, CoQ10 intake led to a significant reduction in serum interleukin 6 (IL-6) (-1.7 &plusmn; 1.6 vs. 0.8 &plusmn; 1.7 ng/l, P &lt; 0.001) and protein carbonyl (PCO) levels (-0.2 &plusmn; 0.3 vs. 0.1 &plusmn; 0.2 nmol/mg protein, P &lt; 0.001). Supplementation with CoQ10 did not affect serum lipoprotein(a), advanced glycation end-products and thiol concentrations compared with the placebo.</p> <p><strong>CONCLUSION:</strong> Overall, this study indicated that CoQ10 intake after 8 weeks among diabetic patients with the stable CHD had beneficial effects on serum IL-6 and PCO levels, but did not alter other cardiometabolic markers.&nbsp;</p><p>&nbsp;